STOCK TITAN

IQVIA Announces Offering of Senior Notes

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

IQVIA Holdings Inc. (NYSE:IQV) plans to raise €1.45 billion (approximately $1.76 billion) through an offering of senior notes due 2026 and 2029. The proceeds will be used to redeem all outstanding 3.250% senior notes due 2025, including premiums, and to cover fees related to the offering. The completion of the notes offering is subject to market and customary conditions. The company emphasizes that this does not constitute an offer to sell or solicit buyers, and the notes will not be registered under the Securities Act of 1933.

Positive
  • Raising €1.45 billion to strengthen capital structure.
  • Redeeming higher interest 3.250% senior notes could reduce interest expenses.
  • Offering could enhance liquidity and financial flexibility.
Negative
  • Potential market conditions may not support the consummation of the offering.
  • Risk of dilution if additional financing is sought.

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise €1,450,000,000 in gross proceeds (equivalent to approximately $1,761,000,000) through an offering of senior notes due 2026 and senior notes due 2029 (collectively, the “Notes”). IQVIA also announced that the Issuer intends to deliver a notice of redemption with respect to its outstanding 3.250% senior notes due 2025 (the “3.250% Notes”).

The proceeds from the Notes offering will be used to redeem all of the Issuer’s 3.250% Notes, including the payment of premiums in respect thereof, and to pay fees and expenses related to the Notes offering. The consummation of the Notes offering is subject to market and other customary conditions.

Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering and potential changes in market conditions that could cause actual results to differ materially.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 70,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.

IQVIAFIN

FAQ

What is IQVIA's recent senior notes offering?

IQVIA announced a €1.45 billion offering of senior notes due 2026 and 2029 to strengthen its capital structure and redeem existing higher-interest notes.

How will IQVIA use the proceeds from the notes offering?

The proceeds will be used to redeem outstanding 3.250% senior notes due 2025 and to pay related fees and expenses.

What are the risks associated with IQVIA's notes offering?

The offering is subject to market conditions, and there's a risk of dilution if further financing is needed.

When is the maturity date for IQVIA's new senior notes?

The new senior notes will mature in 2026 and 2029.

IQVIA Holdings Inc.

NYSE:IQV

IQV Rankings

IQV Latest News

IQV Stock Data

35.96B
179.82M
0.92%
94.4%
1.44%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States of America
DURHAM